February 4, 2026Third Arc Bio Announces $52M Series A Extension to Expand Oncology and Immunology & Inflammation PortfolioView Press Release
November 13, 2025Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T-Cell Engagers Utilizing SAFEbody® TechnologyView Press Release
March 13, 2025Third Arc Bio Announces First Patient Dosed in Phase 1 Clinical Trial of Lead T Cell Engager ARC101 to Treat CLDN6 Positive CancersView Press Release
